LYMPHIR
Growthdenileukin diftitox-cxdl
BLAINJECTIONINJECTABLE
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LYMPHIR (denileukin diftitox-cxdl) is diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (dt) to cells which express the il-2 receptor. First approved in 2024.
Drug data last refreshed 14h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYMPHIR (denileukin diftitox-cxdl) is a CD25-directed cytotoxin fusion protein that combines diphtheria toxin with IL-2 receptor targeting to eliminate IL-2R-expressing tumor cells and immunosuppressive regulatory T cells. The drug works by binding to CD25 (IL-2 receptor alpha), entering cells, and releasing active diphtheria toxin fragments that inhibit protein synthesis and trigger apoptosis. Approved in August 2024, it represents a novel approach to overcoming tumor immune evasion.
Growth
As a newly approved injectable biologic in growth phase, the product will demand rapid commercial infrastructure build and field team expansion over the next 24-36 months.
Mechanism of Action
diftitox-cxdl is a fusion protein designed to direct the cytocidal action of diphtheria toxin (DT) to cells which express the IL-2 receptor. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl…
Pharmacologic Class:
CD25-directed Cytotoxin
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LYMPHIR represents a rare opportunity to build commercial infrastructure for a novel biologic mechanism from launch; early-career professionals joining the brand now will gain visibility across all phases of oncology go-to-market execution, including payer negotiations, HCP education, and market expansion. Career trajectory accelerates in growth-phase biologics, with potential for regional/global leadership roles as the franchise scales over 3-5 years.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.